CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity

Oncogene

Volumn 33, Issue 15, 2014, Pages 1912-1921

  Zucchini, C ^a   Manara, M C ^b   Pinca, R S ^b   De Sanctis, P ^a   Guerzoni, C ^b   Sciandra, M ^b   Lollini, P L ^a   Cenacchi, G ^c   Picci, P ^b   Valvassori, L ^a   Scotlandi, K ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ARP2 3; cadherins; CD99; ezrin; osteosarcoma; ROCK2

Indexed keywords

ACTIN CYTOSKELETON; ANTIGENS, CD; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETAL PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84899447066     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.152     Document Type: Article

References (63)

1. Levy R, Dilley J, Fox RI, Warnke R. A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76: 6552-6556
2. Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997; 159: 2250-2258
3. Bernard G, Breittmayer JP, De Matteis M, Trampont P, Hofman P, Senik A, et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997; 158: 2543-2550
4. Bernard G, Raimondi V, Alberti I, Pourtein M, Widjenes J, Ticchioni M, et al. CD99 (E2) upregulates alpha4beta1-dependent T-cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol 2000; 30: 3061-3065
5. Bernard G, Zoccola D, Deckert M, Breittmayer JP, Aussel C, Bernard A. The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4 CD8 thymocytes. J Immunol 1995; 154: 26-32
6. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: Actin and zyxin as key intracellular mediators. Oncogene 2004; 23: 5664-5674
7. Husak Z, Printz D, Schumich A, Potschger U, Dworzak MN. Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. J Leukoc Biol 2010; 88: 405-412
8. Imbert AM, Belaaloui G, Bardin F, Tonnelle C, Lopez M, Chabannon C. CD99 expressed on human mobilized peripheral blood CD34 cells is involved in transendothelial migration. Blood 2006; 108: 2578-2586
9. Jung KC, Kim NH, Park WS, Park SH, Bae Y. The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett 2003; 554: 478-484
10. Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspaseindependent T-cell death. J Immunol 2001; 166: 4931-4942
11. Schenkel AR, Dufour EM, Chew TW, Sorg E, Muller WA. The murine CD99-related molecule CD99-like 2 (CD99L2) is an adhesion molecule involved in the inflammatory response. Cell Commun Adhes 2007; 14: 227-237
12. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143-150
13. Sohn HW, Choi EY, Kim SH, Lee IS, Chung DH, Sung UA, et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. Am J Pathol 1998; 153: 1937-1945
14. Dworzak MN, Froschl G, Printz D, Zen LD, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: Implications for flow cytometric detection of minimal residual disease. Leukemia 2004; 18: 703-708
15. Dworzak MN, Fritsch G, Fleischer C, Printz D, Froschl G, Buchinger P, et al. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-Associated patterns of normal B-lymphopoiesis. Br J Haematol 1999; 105: 690-695
16. Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006; 17: 1910-1921
17. Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 2007; 26: 6604-6618
18. Kim SH, Shin YK, Lee IS, Bae YM, Sohn HW, Suh YH, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 downregulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 2000; 95: 294-300
19. Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, et al. CD99 isoforms expression dictates T-cell functional outcomes. FASEB J 2002; 16: 1946-1948
20. Lee EJ, Lee HG, Park SH, Choi EY, Park SH. CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells. Exp Mol Med 2003; 35: 438-447
21. Byun HJ, Hong IK, Kim E, Jin YJ, Jeoung DI, Hahn JH, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 2006; 281: 34833-34847
22. D'Souza-Schorey C. Disassembling adherens junctions: Breaking up is hard to do. Trends Cell Biol 2005; 15: 19-26
23. Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004; 48: 463-476
24. Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, et al. Anomalous cadherin expression in osteosarcoma. Possible relationships to metastasis and morphogenesis. Am J Pathol 1999; 155: 1549-1555
25. Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003; 104: 147-154
26. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membranecytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-186
27. Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, Park YK. Ezrin in osteosarcoma: Comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 2006; 202: 509-515
28. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220: 24-33
29. Nurnberg A, Kitzing T, Grosse R. Nucleating actin for invasion. Nat Rev Cancer 2011; 11: 177-187
30. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446-456
31. Zheng S, Huang J, Zhou K, Zhang C, Xiang Q, Tan Z, et al. 17beta-estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS One 2011; 6: E22439
32. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012; 31: 269-281
33. Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009; 41: 138-144
34. Jiao X, Katiyar S, Liu M, Mueller SC, Lisanti MP, Li A, et al. Disruption of c-Jun reduces cellular migration and invasion through inhibition of c-Src and hyperactivation of ROCK II kinase. Mol Biol Cell 2008; 19: 1378-1390
35. Lee HH, Tien SC, Jou TS, Chang YC, Jhong JG, Chang ZF. Src-dependent phosphorylation of ROCK participates in regulation of focal adhesion dynamics. J Cell Sci 2010; 123: 3368-3377
36. Pankova K, Rosel D, Novotny M, Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci 2010; 67: 63-71
37. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. Compensation mechanism in tumor cell migration: Mesenchymal-Amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-277
38. Otsubo T, Iwaya K, Mukai Y, Mizokami Y, Serizawa H, Matsuoka T, et al. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol 2004; 17: 461-467
39. Laurila E, Savinainen K, Kuuselo R, Karhu R, Kallioniemi A. Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. Genes Chromosomes Cancer 2009; 48: 330-339
40. Hall A, Nobes CD. Rho GTPases: Molecular switches that control the organization and dynamics of the actin cytoskeleton. Philosl TransR Soc LonB, Biolog Sci 2000; 355: 965-970
41. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: Integrating signals from front to back. Science 2003; 302: 1704-1709
42. Jaganathan BG, Ruester B, Dressel L, Stein S, Grez M, Seifried E, et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 2007; 25: 1966-1974
43. Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thromb Res 2010; 125: E323-e328
44. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, et al. Inhibition of Rhokinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 2005; 65: 8792-8800
45. Zhang X, Li C, Gao H, Nabeka H, Shimokawa T, Wakisaka H, et al. Rho kinase inhibitors stimulate the migration of human cultured osteoblastic cells by regulating actomyosin activity. Cell Mol Biol Lett 2011; 16: 279-295
46. Yoneda A, Multhaupt HA, Couchman JR. The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol 2005; 170: 443-453
47. Lock FE, Ryan KR, Poulter NS, Parsons M, Hotchin NA. Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One 2012; 7: E31423
48. Yoneda A, Ushakov D, Multhaupt HA, Couchman JR. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and-II. Mol Biol Cell 2007; 18: 66-75
49. Croft DR, Sahai E, Mavria G, Li S, Tsai J, Lee WM, et al. Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 2004; 64: 8994-9001
50. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003; 9: 2632-2641
51. Vishnubhotla R, Sun S, Huq J, Bulic M, Ramesh A, Guzman G, et al. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest 2007; 87: 1149-1158
52. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y, et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004; 10: 4799-4805
53. Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 2009; 49: 1583-1594
54. Yu H, Zhang Y, Ye L, Jiang WG. The FERM family proteins in cancer invasion and metastasis. Front Biosci 2011; 16: 1536-1550
55. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007; 24: 69-78
56. Nakamura H, Ozawa H. Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiae. J Bone Miner Res 1996; 11: 1715-1722
57. Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, et al. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 2004; 164: 653-659
58. Hamada K, Shimizu T, Matsui T, Tsukita S, Hakoshima T. Structural basis of the membrane-Targeting and unmasking mechanisms of the radixin FERM domain. EMBO J 2000; 19: 4449-4462
59. Louvet-Vallee S. ERM proteins: From cellular architecture to cell signaling. Biol cell 2000; 92: 305-316
60. Zhang Y, Li X, Qi J, Wang J, Liu X, Zhang H, et al. Rock2 controls TGFbeta signaling and inhibits mesoderm induction in zebrafish embryos. J Cell Sci 2009; 122: 2197-2207
61. Rivat C, De Wever O, Bruyneel E, Mareel M, Gespach C, Attoub S. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. Oncogene 2004; 23: 3317-3327
62. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006; 32: 423-436
63. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154-1161